Revolutionary Gold-Based Drugs Show 82% Reduction in Tumor Growth

**Researchers at RMIT University** have developed a groundbreaking gold-based compound that dramatically reduces tumor growth by 82% in animals, a significant improvement over the 29% reduction seen with cisplatin, a standard chemotherapy drug. This new compound is 27 times more potent against cervical cancer cells in vitro and also demonstrates superior effectiveness against prostate cancer and fibrosarcoma cells. One of the key advantages of this compound is its ability to selectively target cancer cells with **minimal toxicity to healthy cells**, a stark contrast to the often harsh side effects of platinum-based drugs. The gold compound works by interacting with the enzyme **thioredoxin reductase**, abundant in cancer cells, effectively shutting down cancer cell proliferation and overcoming drug resistance. The compound also inhibits angiogenesis—the formation of new blood vessels essential for tumor growth—highlighting its multi-faceted approach against cancer. This project, led by Professors **Suresh Bhargava** and **Magdalena Plebanski**, involves collaboration with the Indian Institute of Chemical Technology and is supported by a $2 million Australia-India Strategic Research Fund grant. Drawing historical inspiration from gold's use in Ayurvedic treatments, the researchers are paving the way for gold's **scientific validation** as a cancer therapy. The global interest from gold producers like ABC Bullion and Agnico Eagle Mines underscores the social and scientific impact of this research, marking it as a significant step toward addressing a global health challenge.